2614 Boston Post Road Suite #33B
Guilford CT 06327 | USA
Our Goals are Anything but Artificial, Together we will Innovate with Intelligence.
AlphaMeld® is decoding the Gut-Brain Axis (GBA) and inflammasome pathways to drive a pipeline of therapies addressing chronic inflammatory diseases of the gut based on high unmet medical need, while maximizing localized efficacy and reducing systemic side-effects compared with the current standard of care.
Teams will work together by leveraging InveniAI's technology
April 27, 2021
Expansion of existing collaboration will leverage InveniAI
December 09, 2020
Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial
September 09, 2020
Three-year strategic collaboration to leverage InveniAI’s AI
July 29, 2020